Tokyo, Japan and London, UK, 7 November 2018 – Sosei Group Corporation (“Sosei” or “the Company”; TSE: 4565), announces that its wholly owned subsidiary Heptares Therapeutics has entered a new collaboration agreement designed to extend its leadership in GPCR medicine design and accelerate new drug discovery.
The collaboration agreement with Germany-based DyNAbind GmbH aims to pioneer the application of next-generation DNA-based technologies against Stabilized Receptor (StaR®) proteins to rapidly generate and optimize selective and potent small molecule drug candidates for multiple GPCR drug targets, including historically hard-to-drug targets.
Dr Malcolm Weir, Executive Vice President and Chief R&D Officer, said: “This exciting collaboration offers an opportunity to enhance further our world-leading StaR® technology and structure-based drug discovery platform. By working with DyNAbind to deploy the very latest advances in DNA-encoded library technologies with StaR® proteins we are adding a new approach to generate drug candidates to progress into our pipeline. This represents yet another example of how the Company is seeking out cutting-edge technologies to strengthen our platform and discovery capabilities and thereby maximize the long-term value we can derive from StaR® proteins.”
Financial terms of the collaboration are not disclosed. There are no material financial costs to the Company under the collaboration agreement, and Sosei retains all rights to advance the best compounds into discovery and development.